WILMINGTON -
As a member of the executive leadership team,
'We are thrilled to welcome Jo to NiKang at this pivotal time as we are accelerating the development of our product pipeline. Her extensive medical experience and proven track record in the global pharmaceutical and biotech industry will help us effectively execute our clinical programs including NKT2152, a potential best-in-class HIF2 inhibitor; NKT3447, a potential first-in-class cyclin E-reducing CDK2 selective inhibitor and future CDK2 specific degraders for the treatment of solid tumors', said
'NiKang has built an attractive portfolio of innovative oncology medicines and a highly productive research engine,' said
About NiKang Therapeutics
NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.
Contact:
Email: IR@nikangtx.com
Tel: (302) 415-5127
Fax: (212) 478-8615
Email: info@nikangtx.com
(C) 2024 Electronic News Publishing, source